Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Legislation

Set Alert for Legislation

Latest From Legislation

Drug Pricing Legislation Appears Nowhere In Sight Following Senate Hearing

Senators and witnesses rehashed years-old arguments and found little common ground on which elements of drug pricing to address.

Pricing Debate Reimbursement

Antibiotic Incentives: Prize Fund Is Focus Of Presidential Report On Incentives

Upcoming White House report on antibiotic incentives will provide a strong endorsement of one-time payments to reward successful development of new therapeutics. That is a mixed blessing for advocates for legislative action for incentives who are focusing on 'wildcard' patents.

Infectious Diseases Intellectual Property

Delay Means New EU Clinical Trial Rules May Not Be Transferred To UK

With the implementation of the EU Clinical Trials Regulation now postponed to the second half of 2019, it is unlikely that its provisions will be taken over into UK legislation as part of the Brexit “Repeal Bill” that will convert all EU laws and regulations into domestic UK law.

Clinical Trials Brexit

Canada Prepares To Publish Draft Rules On Release Of Clinical Data

Following a public consultation earlier this year, Health Canada has asked for expert advice on its plans to allow the release of clinical data that is currently considered confidential. It expects to publish draft regulations this autumn.

Clinical Trials Canada

340B Providers Offer Varying Approaches To Tracking, Using Discounts At Hearing

House Energy and Commerce Committee Chair Greg Walden, R-Ore., expresses frustration at lack of reliable data on the way providers account for 340B drug discounts at Oct. 11 hearing.

Pricing Strategies Legislation

California Enacts Tough Drug Price Reporting Law

Rx manufacturers must notify state purchasers, health care plans and PBMs of price hikes on drugs with a wholesale acquisition cost greater than $40; follows at least five other state laws, including those of Vermont and Nevada.

Pricing Debate Legislation
See All
UsernamePublicRestriction

Register